רווחיות מכירות לפי רווח נקי: krystalbio.com (KRYS)

סמלים רשמיים של חברת Krystal Biotech Inc (KRYS)

Strong R&D management led by Krish Krishnan ensured the success of the first topical gene therapy for Krystal Biotech, Inc. (KRYS). This chart on GURU.Markets displays the net margin, where the value 47.90 captures current efficiency. Robotic bioreactors optimize production by reducing manual labor. However, fierce competition in the biotech sector creates risks of losing market position should any delays occur in drug trials.

Krystal Biotech, Inc. (KRYS) - שולי רווח נקי ממכירות מ-04.07.2022 עד 20.11.2026

Krystal Corp (KRYS) - פילוחי מדדים ודוחות פיננסיים

- שווי שוק ותחזית יעד של אנליסטים:
הערכת שווי פונדמנטלית:Krystal Biotech Inc - KRYS
מוצרים מוגמרים של Krystal Biotech Inc

The commercialization of the first gene therapy for skin pathologies and the management of insurance reimbursements directly determine the operational efficiency of Krystal Biotech, Inc. (KRYS). The ratio of net income to revenue, reflected in the company's net profit margin, measures the actual income share from every dollar of sales, allowing investors to differentiate real business profitability from market overheating or asset illiquidity risk.